“Goldman Sachs: These 3 Stocks Could Spike Over 60%”
July 19, 2021
“Ambrx Biopharma (AMAM)…
This new biopharma stock has a Strong Buy rating from the analyst consensus, based on 3 positive reviews so far. The shares are priced at $19.56 and their $39.50 average target suggests room for an upside of 101% this coming year.
Lyell Immunopharma (LYEL)…
Again, this is a newly-public biopharma with a unanimous Strong Buy consensus; Lyell has received 4 positive reviews in its short time on the markets. The stock is currently trading at $16.91, with a $25.50 average price target that implies a one-year upside of 51%.
WalkMe (WKME)…
Tech unicorns typically garner plenty of attention, and WalkMe is no exception. The company has picked up new fewer than 9 analyst reviews in its first weeks on the market – and all are positive, backing a Strong Buy consensus rating. The shares are priced at $29.06; their average target of $40 suggests a 37% one-year upside potential…”
https://finance.yahoo.com/news/goldman-sachs-3-stocks-could-153951125.html